

Pierre Ronco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2529021/publications.pdf>

Version: 2024-02-01

87
papers

5,152
citations

117453

34
h-index

95083

68
g-index

88
all docs

88
docs citations

88
times ranked

3458
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of PLA2R antibody monitoring: what we know and what we do not know. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 826-833.	0.4	6
2	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581.	2.1	15
3	Contactin 1, a Potential New Antigen Target in Membranous Nephropathy: A Case Report. <i>American Journal of Kidney Diseases</i> , 2022, 80, 289-294.	2.1	8
4	Recurrence of Anti-Semaphorin 3B-Mediated Membranous Nephropathy after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 503-509.	3.0	17
5	Incremental and Personalized Hemodialysis Start: A New Standard of Care. <i>Kidney International Reports</i> , 2022, 7, 1049-1061.	0.4	18
6	Cubilin and amnionless protein are novel target antigens in anti-brush border antibody disease. <i>Kidney International</i> , 2022, 101, 1063-1068.	2.6	4
7	Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy. <i>Kidney International Reports</i> , 2022, 7, 1539-1556.	0.4	8
8	Tribute to Jan Weening (1950-2022). <i>Kidney International</i> , 2022, 101, 840-842.	2.6	0
9	A challenge to the kidney community by a man-made crisis. <i>Kidney International</i> , 2022, 101, 854-855.	2.6	3
10	Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study. <i>Kidney International Reports</i> , 2022, , .	0.4	1
11	The clinicopathologic spectrum of segmental membranous glomerulopathy. <i>Kidney International</i> , 2021, 99, 247-255.	2.6	30
12	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2021, 99, 2-4.	2.6	1
13	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	2.6	24
14	Membranous nephropathy: current understanding of various causes in light of new target antigens. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 287-293.	1.0	28
15	Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans. <i>BMC Nephrology</i> , 2021, 22, 15.	0.8	4
16	Advances in Membranous Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 607.	1.0	53
17	Management of acute kidney injury in symptomatic multiple myeloma. <i>Kidney International</i> , 2021, 99, 570-580.	2.6	31
18	Looking back and moving forward. <i>Kidney International</i> , 2021, 99, 787-790.	2.6	1

#	ARTICLE	IF	CITATIONS
19	Protocadherin 7â€“Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 1249-1261.	3.0	92
20	Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney International, 2021, 99, 1275-1279.	2.6	60
21	Antenatal Membranous Nephropathy and Type 2 (Axonal) Charcot-Marie-Tooth With Mutations in the Metallo-Membrane Endopeptidase Gene: A Call for Family Screening and Pharmacovigilance. Kidney International Reports, 2021, 6, 1981-1986.	0.4	0
22	Membranous nephropathy. Nature Reviews Disease Primers, 2021, 7, 69.	18.1	167
23	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	2.6	325
24	When contactin antibodies hit the podocyte: a new neurorenal syndrome. Kidney International, 2021, 100, 1163-1165.	2.6	5
25	Contactin-1â€“associated membranous nephropathy: complete immunologic and clinical remission with rituximab. Kidney International, 2021, 100, 1342-1344.	2.6	10
26	Membranous Nephropathy. , 2021, , 1-23.		4
27	Molecular Pathogenesis of Membranous Nephropathy. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 287-313.	9.6	71
28	Neural epidermal growth factor-like 1 proteinâ€“(NELL-1) associated membranous nephropathy. Kidney International, 2020, 97, 163-174.	2.6	213
29	Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy. Kidney International Reports, 2020, 5, 182-188.	0.4	14
30	Rituximab in Patients With Phospholipase A2 Receptorâ€“Associated Membranous Nephropathy and Severe CKD. Kidney International Reports, 2020, 5, 331-338.	0.4	23
31	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andâ€“managing kidney cancer. Kidney International, 2020, 98, 1108-1119.	2.6	26
32	Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Kidney International, 2020, 98, 1308-1322.	2.6	39
33	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	5.8	120
34	How to assess kidney function in oncology patients. Kidney International, 2020, 97, 894-903.	2.6	9
35	Semaphorin 3Bâ€“associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney International, 2020, 98, 1253-1264.	2.6	138
36	Standardized reporting of monoclonal immunoglobulinâ€“associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	2.6	7

#	ARTICLE	IF	CITATIONS
37	Aside from acute renal failure cases, are urinary markers of glomerular and tubular function useful in clinical practice?. <i>Clinical Biochemistry</i> , 2019, 65, 1-6.	0.8	6
38	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	2.6	47
39	From podocyte biology to novel cures for glomerular disease. <i>Kidney International</i> , 2019, 96, 850-861.	2.6	49
40	Exostosin 1/Exostosin 2-associated Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1123-1136.	3.0	198
41	Efficacy of Rituximab in a Patient With Partial Clinical Remission and Persistent Circulating PLA2R-Ab. <i>Kidney International Reports</i> , 2019, 4, 1027-1030.	0.4	1
42	Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. <i>BJU International</i> , 2019, 124, 849-861.	1.3	30
43	Citius, altius, fortius . . . faster, higher, stronger. <i>Kidney International</i> , 2019, 95, 476-478.	2.6	4
44	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. <i>Kidney International</i> , 2019, 95, 666-679.	2.6	68
45	Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 596-604.	2.1	24
46	Kidney International celebrates the 60th anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2019, 96, 1248-1249.	2.6	2
47	Decreased expression of megalin and cubilin and altered mitochondrial activity in tenofovir nephrotoxicity. <i>Human Pathology</i> , 2018, 73, 89-101.	1.1	16
48	Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. <i>Kidney International</i> , 2018, 93, 1016-1017.	2.6	50
49	Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome. <i>Pediatric Nephrology</i> , 2018, 33, 473-483.	0.9	34
50	The Role of PLA2R Antibody in Treatment of Membranous Nephropathy. <i>Kidney International Reports</i> , 2018, 3, 498-501.	0.4	12
51	The authors reply. <i>Kidney International</i> , 2018, 94, 830.	2.6	0
52	The Bowman's shield: a tribute to translational science and Detlef Schlöndorff. <i>Kidney International</i> , 2018, 94, 448-450.	2.6	0
53	Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2000-2013.	3.0	72
54	Circulating antibodies to Î±-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 117-126.	0.7	33

#	ARTICLE	IF	CITATIONS
55	Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 348-358.	3.0	286
56	Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics. <i>Talanta</i> , 2017, 164, 77-84.	2.9	24
57	HANAC Col4a1 Mutation in Mice Leads to Skeletal Muscle Alterations due to a Primary Vascular Defect. <i>American Journal of Pathology</i> , 2017, 187, 505-516.	1.9	28
58	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. <i>Blood</i> , 2017, 129, 1437-1447.	0.6	120
59	Col4a1 mutation generates vascular abnormalities correlated with neuronal damage in a mouse model of HANAC syndrome. <i>Neurobiology of Disease</i> , 2017, 100, 52-61.	2.1	9
60	B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. <i>Kidney International</i> , 2017, 92, 227-237.	2.6	102
61	Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. <i>American Journal of Kidney Diseases</i> , 2017, 70, 874-877.	2.1	10
62	MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1651-1664.	3.0	82
63	Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. <i>PLoS ONE</i> , 2017, 12, e0173201.	1.1	59
64	Extracorporeal shock wave therapy does not improve hypertensive nephropathy. <i>Physiological Reports</i> , 2016, 4, e12699.	0.7	7
65	Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. <i>Kidney International</i> , 2016, 89, 1399.	2.6	16
66	Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1275-1277.	3.0	23
67	Impaired Lysosomal Function Underlies Monoclonal Light Chain-associated Renal Fanconi Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2049-2061.	3.0	52
68	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	3.0	44
69	HANAC Syndrome Col4a1 Mutation Causes Neonate Glomerular Hyperpermeability and Adult Glomerulocystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1042-1054.	3.0	40
70	Epidemiology of Histologically Proven Glomerulonephritis in Africa: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0152203.	1.1	46
71	Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1047-1050.	0.4	51
72	Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. <i>Kidney International</i> , 2015, 87, 602-609.	2.6	57

#	ARTICLE	IF	CITATIONS
73	Moderator's view: Biomarkers in glomerular diseases—translated into patient care or lost in translation?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 899-902.	0.4	5
74	Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. <i>Lancet, The</i> , 2015, 385, 1983-1992.	6.3	265
75	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2545-2558.	3.0	280
76	Nephrology research—the past, present and future. <i>Nature Reviews Nephrology</i> , 2015, 11, 677-687.	4.1	23
77	Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. <i>Molecular Immunology</i> , 2015, 68, 57-62.	1.0	20
78	Acute metabolic acidosis in a GLUT2-deficient patient with Fanconi-Bickel syndrome: new pathophysiology insights. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv113-iv116.	0.4	15
79	Increased risk of solid renal tumors in lithium-treated patients. <i>Kidney International</i> , 2014, 86, 184-190.	2.6	62
80	Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1735-1743.	3.0	270
81	Pathophysiological lessons from rare associations of autoimmune diseases. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 91-93.	1.4	0
82	Patterns of Noncryoglobulinemic Glomerulonephritis with Monoclonal Ig Deposits. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1609-1616.	2.2	114
83	Risk HLA-DQA1 and PLA ₂ R1 Alleles in Idiopathic Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2011, 364, 616-626.	13.9	442
84	PLA ₂ R Autoantibodies and PLA ₂ R Glomerular Deposits in Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2011, 364, 689-690.	13.9	277
85	Nephrotic syndrome associated with immune thrombocytopenia revealing Kimura's disease in a non-Asian male. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 452-454.	1.4	5
86	Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. <i>Kidney International</i> , 2008, 74, 873-878.	2.6	70
87	NONNEPHROTOXIC, DYNAMIC, CONTRAST ENHANCED MAGNETIC RESONANCE UROGRAPHY: USE IN NEPHROLOGY AND UROLOGY. <i>Journal of Urology</i> , 2000, 163, 1191-1196.	0.2	27